Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease

Free Radical Biology and Medicine

Volumn 67, Issue , 2014, Pages 387-395

  Farr, Susan A ^a   Ripley, Jessica L ^b   Sultana, Rukhsana ^b   Zhang, Zhaoshu ^b   Niehoff, Michael L ^a   Platt, Thomas L ^c   Murphy, M Paul ^c   Morley, John E ^a,d   Kumar, Vijaya ^a,d   Butterfield, D Allan ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease (AD); Antisense; Glycogen synthase kinase 3 (GSK 3 ); Nuclear factor E2 related factor 2 (Nrf2); Oxidative stress; SAMP8 mice

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA ACTIN; GLUTATHIONE TRANSFERASE; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE H2B; TAU PROTEIN; TRANSCRIPTION FACTOR NRF2; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NFE2L2 PROTEIN, MOUSE; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOSOL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG TRANSPORT; IMMUNOBLOTTING; IMMUNOCHEMISTRY; LEARNING; LIPID PEROXIDATION; MALE; MEMORY; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SENESCENCE ACCELERATED MOUSE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HUMAN; MAZE TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PATTERN RECOGNITION; PHOSPHORYLATION; PHYSIOLOGY; PROCEDURES; PROTEIN CARBONYLATION;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC THERAPY; GLUTATHIONE TRANSFERASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MAZE LEARNING; MEMORY; MICE; NF-E2-RELATED FACTOR 2; OLIGONUCLEOTIDES, ANTISENSE; OXIDATIVE STRESS; PATTERN RECOGNITION, VISUAL; PHOSPHORYLATION; PROTEIN CARBONYLATION; REACTIVE OXYGEN SPECIES; TAU PROTEINS;

EID: 84891589937     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.11.014     Document Type: Article

References (57)

1. A.S. Association 2013 Alzheimer's disease facts and figures Alzheimer's Dement 9 2013 208 245
2. L.K. Clinton, M. Blurton-Jones, K. Myczek, J.Q. Trojanowski, and F.M. LaFerla Synergistic Interactions between Abeta, tau, and alpha-synuclen: acceleration of neuropathology and cognitive decline J. Neurosci. 30 2010 7281 7289
3. S. Mondragon-Rodriguez, G. Perry, X. Zhu, P.I. Moreira, and S. Williams Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target Int. J. Alzheimer's Dis. 2012 2012 1 4
4. J.R. Woodgett Judging a protein by more than its name: GSK-3 Sci STKE 2001 2001 re12
5. J.H. Cho, and G.V. Johnson Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules J. Neurochem. 88 2004 349 358 (Pubitemid 38084551)
6. T. Engel, P. Goni-Oliver, J.J. Lucas, J. Avila, and F. Hernandez Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert J. Neurochem. 99 2006 1445 1455 (Pubitemid 44924224)
7. C. Hooper, R. Killick, and S. Lovestone The GSK3 hypothesis of Alzheimer's disease J. Neurochem. 104 2008 1433 1439 (Pubitemid 351316776)
8. D.E. Hurtado, L. Molina-Porcel, J.C. Carroll, C. Macdonald, A.K. Aboagye, J.Q. Trojanowski, and V.M. Lee Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease J. Neurosci. 32 2012 7392 7402
9. J.J. Lucas, F. Hernandez, P. Gomez-Ramos, M.A. Moran, R. Hen, and J. Avila Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice EMBO J. 20 2001 27 39 (Pubitemid 32099099)
10. J.J. Pei, E. Braak, H. Braak, I. Grundke-Iqbal, K. Iqbal, B. Winblad, and R.F. Cowburn Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes J. Neuropathol. Exp. Neurol. 58 1999 1010 1019 (Pubitemid 29441929)
11. L. Sereno, M. Coma, M. Rodriguez, P. Sanchez-Ferrer, M.B. Sanchez, I. Gich, J.M. Agullo, M. Perez, J. Avila, C. Guardia-Laguarta, J. Clarimon, A. Lleo, and T. Gomez-Isla A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo Neurobiol. Dis. 35 2009 359 367
12. G. Alvarez, J.R. Munoz-Montano, J. Satrustegui, J. Avila, E. Bogonez, and J. Diaz-Nido Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration FEBS Lett. 453 1999 260 264 (Pubitemid 29326659)
13. J.R. Woodgett Molecular cloning and expression of glycogen synthase kinase-3/factor A EMBO J. 9 1990 2431 2438
14. P.T. Ly, Y. Wu, H. Zou, R. Wang, W. Zhou, A. Kinoshita, M. Zhang, Y. Yang, F. Cai, J. Woodgett, and W. Song Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes J. Clin. Invest. 123 2013 224 235
15. J.I. Diaz-Hernandez, R. Gomez-Villafuertes, M. Leon-Otegui, L. Hontecillas-Prieto, A. Del Puerto, J.L. Trejo, J.J. Lucas, J.J. Garrido, J. Gualix, M.T. Miras-Portugal, and M. Diaz-Hernandez In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3beta and secretases Neurobiol. Aging 33 2012 1816 1828
16. J. Ryder, Y. Su, F. Liu, B. Li, Y. Zhou, and B. Ni Divergent roles of GSK3 and CDK5 in APP processing Biochem. Biophys. Res. Commun. 312 2003 922 929 (Pubitemid 37490904)
17. C.J. Phiel, C.A. Wilson, V.M. Lee, and P.S. Klein GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides Nature 423 2003 435 439 (Pubitemid 36626994)
18. C.J. Phiel, C.A. Wilson, V.M. Lee, and P.S. Klein GSK-3alpha regulates production of Alzheimer's disease amyloi-beta peptides Nature 423 2003 435
19. A. Takashima GSK-3 is essential in the pathogenesis of Alzheimer's disease J. Alzheimers Dis. 9 2006 309 317 (Pubitemid 44253325)
20. M. Morris, S. Maeda, K. Vossel, and L. Mucke The many faces of tau Neuron 70 2011 410 426
21. D.P. Hanger, K. Hughes, J.R. Woodgett, J.P. Brion, and B.H. Anderton Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase Neurosci. Lett. 147 1992 58 62
22. S. Lovestone, C.H. Reynolds, D. Latimer, D.R. Davis, B.H. Anderton, J.M. Gallo, D. Hanger, S. Mulot, B. Marquardt, and S. Stabel et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells Curr. Biol. 4 1994 1077 1086 (Pubitemid 124001594)
23. M. Hong, D.C. Chen, P.S. Klein, and V.M. Lee Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3 J. Biol. Chem. 272 1997 25326 25332 (Pubitemid 27415724)
24. A.Y. Shih, D.A. Johnson, G. Wong, A.D. Kraft, L. Jiang, H. Erb, J.A. Johnson, and T.H. Murphy Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress J. Neurosci. 23 2003 3394 3406 (Pubitemid 36531981)
25. A.D. Kraft, D.A. Johnson, and J.A. Johnson Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult J. Neurosci 24 2004 1101 1112 (Pubitemid 38177017)
26. V. Calabrese, A. Ravagna, C. Colombrita, G. Scapagnini, E. Guagliano, M. Calvani, D.A. Butterfield, and A.M. Giuffrida Stella Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2 J. Neurosci. Res. 79 2005 509 521 (Pubitemid 40283351)
27. T.P. Williamson, D.A. Johnson, and J.A. Johnson Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity Neurotoxicology 33 2012 272 279
28. S.C. Lo, X. Li, M.T. Henzl, L.J. Beamer, and M. Hannink Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling EMBO J. 25 2006 3605 3617 (Pubitemid 44264871)
29. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, and M. Yamamoto Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Genes Dev. 13 1999 76 86 (Pubitemid 29045117)
30. K. Itoh, T. Ishii, N. Wakabayashi, and M. Yamamoto Regulatory mechanisms of cellular response to oxidative stress Free Radic. Res. 31 1999 319 324 (Pubitemid 29452857)
31. A.T. Dinkova-Kostova, W.D. Holtzclaw, R.N. Cole, K. Itoh, N. Wakabayashi, Y. Katoh, M. Yamamoto, and P. Talalay Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants Proc. Natl. Acad. Sci. USA 99 2002 11908 11913 (Pubitemid 34994497)
32. D.D. Zhang, and M. Hannink Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress Mol. Cell. Biol. 23 2003 8137 8151 (Pubitemid 37377505)
33. H. Yagi, S. Katoh, I. Akiguchi, and T. Takeda Afe-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory Neurosci. Biobehav. Rev. 474 1988 86 93 (Pubitemid 19001185)
34. J.F. Flood, and J.E. Morley Learning and memory in the SAMP8 mouse Neurosci. Biobehav. Rev. 22 1998 1 20 (Pubitemid 28082281)
35. J.E. Morley, V.B. Kumar, A.I. Bernardo, S.A. Farr, K. Uezu, N. Tumosa, and J.F. Flood Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory Peptides 21 2000 1761 1767 (Pubitemid 32058850)
36. M. Pallas, A. Camins, M.A. Smith, G. Perry, H.G. Lee, and G. Casadesus From aging to Alzheimer's disease: unveiling the switch with the senescence-accelerated mouse model (SAMP8) J. Alzheimers Dis. 15 2008 615 624
37. D.A. Butterfield, and E.R. Stadtman Protein oxidation processes in aging brain Adv. Cell Aging Gerontol 1997 161 191
38. H.F. Poon, A. Castegna, S.A. Farr, V. Thongboonkerd, B.C. Lynn, W.A. Banks, J.E. Morley, J.B. Klein, and D.A. Butterfield Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain Neuroscience 126 2004 915 926 (Pubitemid 38780896)
39. M.A. Erickson, M.L. Niehoff, S.A. Farr, J.E. Morley, L.A. Dillman, K.M. Lynch, and W.A. Banks Peripheral admininstration of antisense oligonucleotides targeting the amyloid-B protein precursor reverses ABPP and LRP-1 overexpression in the aged SAMP8 mouse brain J. Alzheimers Dis. 28 2012 951 960
40. M. Tajes, M. Yeste-Velasco, X. Zhu, S.P. Chou, M.A. Smith, M. Pallas, A. Camins, and G. Casadesus Activation of Akt by lithium: pro-survival pathways in aging Mech. Ageing Dev. 130 2009 253 261
41. R.S. Hammond, L.E. Tull., and R.W. Stackman On the delay-dependent involvement of the hippocampus in object recognition memory Neurobiol. Learn. Mem. 82 2004 26 34 (Pubitemid 38737427)
42. P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Olson, and D.C. Klenk Measurement of protein using bicichoninic acid Anal. Biochem. 150 1985 76 85 (Pubitemid 16258399)
43. R. Sultana, M. Perluigi, and D.A. Butterfield Lipid peroxidation triggers neurodegeneration: a redox prloteomics view into the Alzheimer disease brain Free Radic. Biol. Med. 2012
44. W.A. Banks, L.B. Jaeger, A. Urayama, V.B. Kumar, S.M. Hileman, F.S. Gaskin, N.V. Llanza, S.A. Farr, and J.E. Morley Preproenkephalin targeted antisenses cross the blood-brain barrier to reduce brain methionine enkephalin levels and increase voluntary ethanol drinking Peptides 27 2006 784 796
45. L.B. Jaeger, S. Dohgu, M.C. Hwang, S.A. Farr, M.P. Murphy, M.A. Fleegal-DeMotta, J.L. Lynch, S.M. Robinson, M.L. Niehoff, S.N. Johnson, V.B. Kumar, and W.A. Banks Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition J. Alzheimer's Dis. 17 2009 553 570
46. H. Yamaguchi, K. Ishiguro, T. Uchida, A. Takashima, C.A. Lemere, and K. Imahori Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II Acta Neuropathol. 92 1996 232 241 (Pubitemid 26278953)
47. J.J. Pei, T. Tanaka, Y.C. Tung, E. Braak, K. Iqbal, and I. Grundke-Iqbal Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain J. Neuropathol. Exp. Neurol. 56 1997 70 78 (Pubitemid 127470328)
48. K. Leroy, Z. Yilmaz, and J.P. Brion Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration Neuropathol. Appl. Neurobiol. 33 2007 43 55 (Pubitemid 46090309)
49. R.S. Jope, C.J. Yukaitis, and E. Beurel Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics Neurochem. Res. 32 2007 577 595 (Pubitemid 46481289)
50. A.C. Wild, H.R. Moinova, and R.T. Mulcahy Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2 J. Biol. Chem. 274 1999 33627 33636 (Pubitemid 129511675)
51. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, and Y. Nabeshima An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements Biochem. Biophys. Res. Commun. 236 1997 313 322 (Pubitemid 27373291)
52. R. Malik, and I. Roy Making sense of therapeutics using antisense technology Expert Opin. Drug Discov. 6 2011 507 526
53. I. Tamm AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for potential tretment of cancer Curr. Opin. Investig. Drugs 9 2008 638 646 (Pubitemid 351777167)
54. A.L. Petursdottir, S.A. Farr, J.E. Morley, W.A. Banks, and G.V. Skuladottir Lipid peroxidation in brain during aging in the senescence- accelerated mouse (SAM) Neurbiol. Aging 28 2006 1170 1178
55. H.F. Poon, G. Joshi, R. Sultana, S.A. Farr, W.A. Banks, J.E. Morley, V. Calabrese, and D.A. Butterfield Antisense directed at the Abeta region of the APP decreases brain oxidative maarkers in aged senescence accelerated mice Brain Res. 1018 2004 86 96 (Pubitemid 38942865)
56. W.A. Banks, S.A. Farr, W. Butt, V.B. Kumar, M.W. Franko, and J.E. Morley Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein J. Pharmacol. Exp. Ther. 297 2001 1113 1121 (Pubitemid 32472511)
57. V.B. Kumar, S.A. Farr, J.F. Flood, V. Kamlesh, M. Franko, W.A. Banks, and J.E. Morley Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice Peptides 21 2000 1769 1775 (Pubitemid 32058851)